论文部分内容阅读
目的探讨三磷酸腺苷结合盒F超家族成员2(ABCF2)在卵巢癌组织中的表达及临床意义。方法选取2014年2月-2016年2月在该院进行治疗的卵巢癌患者113例,分为化疗敏感组(79例)和化疗耐药组(34例),两组患者年龄及病理类型比较差异无统计学意义(P>0.05)。两组患者均行肿瘤细胞灭活术及紫杉醇类与铂类联合化疗,采用免疫组化法检测卵巢组织中ABCF2的表达,随访患者化疗耐药情况及生存情况。结果化疗耐药组Ⅲ~Ⅳ期和ABCF2阳性表达比例分别为76.47%和88.24%,明显高于化疗敏感组(P<0.05);ABCF2阳性表达患者1、2年生存率分别为86.80%和39.70%,ABCF2阴性表达患者1、2年生存率分别为92.80%和71.60%,ABCF2阴性表达患者生存率优于ABCF2阳性表达患者(P<0.05)。结论 ABCF2阳性表达可能与卵巢癌患者化疗耐药及生存期有一定的联系,需进一步研究。
Objective To investigate the expression and clinical significance of ABCF2 in ovarian cancer tissue. Methods A total of 113 patients with ovarian cancer who were treated in this hospital from February 2014 to February 2016 were divided into chemotherapy-sensitive group (79 cases) and chemotherapy-resistant group (34 cases). The age and pathological types of the two groups were compared The difference was not statistically significant (P> 0.05). Two groups of patients underwent tumor cell inactivation and paclitaxel and platinum combined chemotherapy, immunohistochemical detection of ovarian tissue ABCF2 expression, follow-up of patients with chemotherapy resistance and survival. Results The rates of Ⅲ ~ Ⅳ and ABCF2 positive expression in chemoresistant group were 76.47% and 88.24%, respectively, which were significantly higher than those in chemosensitive group (P <0.05). The 1- and 2-year survival rates of patients with ABCF2 positive expression were 86.80% and 39.70 %. The 1-year and 2-year survival rates of patients with ABCF2 negative expression were 92.80% and 71.60%, respectively. The survival rate of patients with negative ABCF2 expression was better than that with ABCF2 positive expression (P <0.05). Conclusion The positive expression of ABCF2 may be related to chemoresistance and survival of patients with ovarian cancer, which needs further study.